Description:

Size: 100 microliters

Catalog no.: GENTObs-11341R-A594

Price: 489 EUR

Product details

Subcellular locations

N/A

Gene ID

N/A

Swiss Prot

N/A

Modification site

None

Target Protein/Peptide

CPLX1

Applications

IF(IHC-P)

Excitation emission

590nm/617nm

Concentration

1ug per 1ul

Conjugated with

ALEXA FLUOR® 594

Conjugated

Alexa conjugate 1

Applications with corresponding dilutions

IF(IHC-P)(1:50-200)

Clonality

Polyclonal Antibody

Clone

Polyclonal Antibodies

Other name

Anti-CPLX1 Polyclonal

Purification method

Purified by Protein A.

Also known as

CPLX1 Polyclonal Antibody

Group

Polyclonals and antibodies

Type

Conjugated Primary Antibody

Conjugation

Alexa Fluor,ALEXA FLUOR® 594

Host organism

Rabbit (Oryctolagus cuniculus)

Properties

For facs or microscopy Alexa 1 conjugate.

Specificity

This antibody reacts specifically with CPLX1

Modification

No modification has been applied to this antibody

Antigen Source

KLH conjugated synthetic peptide derived from human CPLX1

Cross reactive species

Human (Homo sapiens), Mouse (Mus musculus), Rat (Rattus norvegicus)

Synonyms

complexin 1; Complexin I; Complexin-1; CPLX1; CPLX1_HUMAN; CPX I; CPX-I; CPX1; Synaphin 2; Synaphin-2; 921-S.

Storage

Water buffered solution containing 100ug/ml BSA, 50% glycerol and 0.09% sodium azide. Store at 4°C for 12 months.

Description

This antibody needs to be stored at + 4°C in a fridge short term in a concentrated dilution. Freeze thaw will destroy a percentage in every cycle and should be avoided.

About

Polyclonals can be used for Western blot, immunohistochemistry on frozen slices or parrafin fixed tissues. The advantage is that there are more epitopes available in a polyclonal antiserum to detect the proteins than in monoclonal sera.

Cross Reactive Species details

No significant cross reactivity has been observed for this antibody for the tested species. However, note that due to limited knowledge it is impossible to predict with 100% guarantee that the antibody does not corss react with any other species.

Advisory

Avoid freeze/thaw cycles as they may denaturate the polypeptide chains of the antibody, thus reducing its reactivity, specificity and sensitivity. For antibodies that are in liquid form or reconstituted lyophilized antibodies small amounts could become entrapped on the seal or the walls of the tube. Prior to use briefly centrifuge the vial to gather all the solution on the bottom.

Background information

Complexin 1 and Complexin 2, also designated Synaphin 1 and Synaphin 2, contain an a-helical middle domain of approximately 58 amino acids. Complexin 1 and Complexin 2 are expressed in presynaptic terminals of inhibitory and excitatory hippocampal neurons, respectively, and in cytoplasmic pools during early stages of development. Complexins promote SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptors) precomplex formation by binding to synaxin with its a-helical domain. Complexins are important regulators of transmitter release at a late step in calcium dependent neurotransmitter release or immediately after the calcium-triggering step of fast synchronous transmitter release and preceding vesicle fusion. Neurons lacking complexins show reduced transmitter release efficiency due to decreased calcium sensitivity of the synaptic secretion process. Complexin 2 may play a role in LTP (long term potentiation) following tetanic stimulation. A progressive loss of Complexin 2 occurs in the brains of mice carrying the Huntington disease mutation, an autosomal dominant neurodegenerative disorder. Changes in the neurotransmitter release might contribute to the motor, emotional and cognitive dysfunctions seen in these mice.